Total Valuation
Bio View has a market cap or net worth of ₪9.47M. The enterprise value is 11.95M.
Market Cap₪9.47M
Enterprise Value11.95M
Share Statistics
Bio View has 13,898,633 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,898,633
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bio View’s return on equity (ROE) is -1.63 and return on invested capital (ROIC) is -62.01%.
Return on Equity (ROE)-1.63
Return on Assets (ROA)-0.77
Return on Invested Capital (ROIC)-62.01%
Return on Capital Employed (ROCE)-0.69
Revenue Per Employee664.33K
Profits Per Employee-511.07K
Employee Count30
Asset Turnover1.00
Inventory Turnover1.84
Valuation Ratios
The current PE Ratio of Bio View is ―. Bio View’s PEG ratio is -0.00401.
PE Ratio―
PS Ratio1.14
PB Ratio2.41
Price to Fair Value2.41
Price to FCF-7.28
Price to Operating Cash Flow20.00
PEG Ratio-0.00401
Income Statement
In the last 12 months, Bio View had revenue of 19.93M and earned -15.33M in profits. Earnings per share was -1.10.
Revenue19.93M
Gross Profit8.75M
Operating Income-7.80M
Pretax Income-9.15M
Net Income-15.33M
EBITDA-7.19M
Earnings Per Share (EPS)-1.10
Cash Flow
In the last 12 months, operating cash flow was 518.00K and capital expenditures -25.00K, giving a free cash flow of 493.00K billion.
Operating Cash Flow518.00K
Free Cash Flow493.00K
Free Cash Flow per Share0.04
Dividends & Yields
Bio View pays an annual dividend of 20, resulting in a dividend yield of <0.01%
Dividend Per Share20
Dividend Yield<0.01%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.13
52-Week Price Change-54.64%
50-Day Moving Average83.22
200-Day Moving Average133.24
Relative Strength Index (RSI)22.24
Average Volume (3m)5.65K
Important Dates
Bio View upcoming earnings date is Nov 18, 2021, TBA (Confirmed).
Last Earnings DateAug 19, 2021
Next Earnings DateNov 18, 2021
Ex-Dividend Date―
Financial Position
Bio View as a current ratio of 1.88, with Debt / Equity ratio of 31.25%
Current Ratio1.88
Quick Ratio1.17
Debt to Market Cap0.06
Net Debt to EBITDA0.30
Interest Coverage Ratio-33.63
Taxes
In the past 12 months, Bio View has paid 6.18M in taxes.
Income Tax6.18M
Effective Tax Rate-0.68
Enterprise Valuation
Bio View EV to EBITDA ratio is -2.86, with an EV/FCF ratio of -6.60.
EV to Sales1.03
EV to EBITDA-2.86
EV to Free Cash Flow-6.60
EV to Operating Cash Flow-6.71
Balance Sheet
Bio View has ₪8.17M in cash and marketable securities with ₪2.10M in debt, giving a net cash position of ₪6.07M billion.
Cash & Marketable Securities₪8.17M
Total Debt₪2.10M
Net Cash₪6.07M
Net Cash Per Share₪0.44
Tangible Book Value Per Share₪0.69
Margins
Gross margin is 49.29%, with operating margin of -39.15%, and net profit margin of -76.93%.
Gross Margin49.29%
Operating Margin-39.15%
Pretax Margin-45.90%
Net Profit Margin-76.93%
EBITDA Margin-36.06%
EBIT Margin-45.30%
Analyst Forecast
The average price target for Bio View is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast15.77%
EPS Growth Forecast-31.40%